## Tatsuro Okamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4104100/publications.pdf

Version: 2024-02-01

89

all docs

88 2,287 26 papers citations h-index

89

docs citations

h-index g-index

89 3900
times ranked citing authors

45

#	Article	IF	CITATIONS
1	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1879-1890.	1.1	156
2	PD-L1 Is Upregulated by Simultaneous Amplification ofÂthe PD-L1 and JAK2 Genes in Non–Small Cell LungÂCancer. Journal of Thoracic Oncology, 2016, 11, 62-71.	1.1	144
3	Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer, 2017, 104, 98-105.	2.0	140
4	Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer, 2016, 101, 92-97.	2.0	105
5	Role of Activating Transcription Factor 3 (ATF3) in Endoplasmic Reticulum (ER) Stress-induced Sensitization of p53-deficient Human Colon Cancer Cells to Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-mediated Apoptosis through Up-regulation of Death Receptor 5 (DR5) by Zerumbone and Celecoxib, Journal of Biological Chemistry, 2014, 289, 21544-21561.	3.4	95
6	Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer. Lung Cancer, 2016, 98, 15-21.	2.0	87
7	Metabolic characteristics of programmed cell deathâ€ligand 1â€expressing lung cancer on <sup>18</sup> Fâ€fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Medicine, 2017, 6, 2552-2561.	2.8	80
8	BAP1 immunohistochemistry and <i>p16</i> FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests. Pathology International, 2016, 66, 563-570.	1.3	75
9	The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer, 2017, 104, 7-15.	2.0	69
10	Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non–Small-cell Lung Cancer: A Mini-review. Clinical Lung Cancer, 2018, 19, 12-16.	2.6	62
11	The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Clinical Lung Cancer, 2018, 19, 120-129.	2.6	61
12	The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 741-748.	1.1	59
13	Preoperative Geriatric Nutritional Risk Index: A predictive and prognostic factor in patients with pathological stage I non-small cell lung cancer. Surgical Oncology, 2017, 26, 483-488.	1.6	55
14	Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. Journal of Thoracic Disease, 2017, 9, 2942-2951.	1.4	53
15	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer, 2018, 116, 1-6.	2.0	51
16	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung CancerÂPatients. Clinical Lung Cancer, 2017, 18, 572-582.e1.	2.6	46
17	Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: a multicentre retrospective study. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 389-394.	1.1	45
18	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surgical Oncology, 2018, 27, 88-94.	1.6	41

#	Article	IF	Citations
19	Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with <i>EGFR</i> Mutations. Clinical Cancer Research, 2014, 20, 3613-3622.	7.0	39
20	Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2018, 25, 1229-1236.	1.5	39
21	Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymphâ€nodeâ€positive lung cancer patients. Cancer Science, 2018, 109, 154-165.	3.9	36
22	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. European Journal of Cancer, 2018, 101, 20-29.	2.8	35
23	Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. Anticancer Research, 2017, 37, 7073-7082.	1.1	32
24	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. PLoS ONE, 2017, 12, e0181598.	2.5	31
25	The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2017, 18, e303-e313.	2.6	30
26	Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 4223-4228.	1.1	30
27	The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer—Differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer, 2014, 85, 125-130.	2.0	29
28	Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. Annals of Thoracic Surgery, 2017, 103, 1750-1757.	1.3	25
29	Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 6997-7003.	1.1	25
30	An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria. Anticancer Research, 2016, 36, 3409-12.	1.1	25
31	Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease. Anticancer Research, 2017, 37, 2735-2742.	1.1	24
32	Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. Anticancer Research, 2016, 36, 4329-36.	1.1	24
33	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Annals of Pharmacotherapy, 2014, 48, 1159-1165.	1.9	23
34	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. Annals of Surgical Oncology, 2018, 25, 1564-1571.	1.5	23
35	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Scientific Reports, 2018, 8, 1005.	3.3	22
36	Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer. Lung Cancer, 2017, 109, 52-57.	2.0	21

#	Article	IF	Citations
37	Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression. Clinical Lung Cancer, 2017, 18, e375-e383.	2.6	18
38	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. Journal of Thoracic Disease, 2015, 7, 1898-906.	1.4	17
39	PICT1 expression is a poor prognostic factor in non-small cell lung cancer. Oncoscience, 2014, 1, 375-382.	2.2	16
40	Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer. Anticancer Research, 2017, 37, 1413-1416.	1.1	16
41	Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 448-454.	1.3	15
42	Prediction of post-operative pulmonary function after lobectomy for primary lung cancer: A comparison among counting method, effective lobar volume, and lobar collapsibility using inspiratory/expiratory CT. European Journal of Radiology, 2016, 85, 1956-1962.	2.6	14
43	Mucinous adenocarcinoma of the thymus: report of a case. General Thoracic and Cardiovascular Surgery, 2018, 66, 111-115.	0.9	14
44	A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. Lung Cancer, 2018, 124, 255-259.	2.0	14
45	Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case. Thoracic Cancer, 2015, 6, 97-100.	1.9	12
46	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non–small-cell lung cancer. Cancer Genetics, 2015, 208, 271-278.	0.4	12
47	High Frequency of Programmed Death-ligand 1ÂExpression in Emphysematous Bullae-associated Lung Adenocarcinomas. Clinical Lung Cancer, 2017, 18, 504-511.e1.	2.6	12
48	Giant Leiomyoma Arising from the Mediastinal Pleura: A Case Report. Annals of Thoracic and Cardiovascular Surgery, 2017, 23, 153-156.	0.8	12
49	Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer. Anticancer Research, 2016, 36, 6319-6326.	1.1	11
50	Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma. Anticancer Research, 2016, 36, 3057-63.	1,1	11
51	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. Surgical Oncology, 2018, 27, 637-641.	1.6	10
52	Surgical treatment for non-small cell lung cancer with ipsilateral pulmonary metastases. Surgery Today, 2013, 43, 1123-1128.	1.5	9
53	Prognostic Significance of Expression of the Epithelial-Mesenchymal Transition-Related Factor Brachyury in Intrathoracic Lymphatic Spread of Non-Small Cell Lung Cancer. Annals of Surgical Oncology, 2016, 23, 1012-1020.	1.5	9
54	miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth <i>In Vivo</i> . Anticancer Research, 2018, 38, 5693-5701.	1.1	9

#	Article	IF	Citations
55	Surgical results of resectable small cell lung cancer. Thoracic Cancer, 2015, 6, 141-145.	1.9	8
56	Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 1393-1402.	1.1	8
57	Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience. Thoracic Cancer, 2013, 4, 66-70.	1.9	7
58	Invasive features of small-sized lung adenocarcinoma adjoining emphysematous bullae. European Journal of Cardio-thoracic Surgery, 2018, 53, 372-378.	1.4	7
59	Surgical Repair of Pleuroperitoneal Communication with Continuous Ambulatory Peritoneal Dialysis. Thoracic and Cardiovascular Surgeon, 2019, 67, 147-150.	1.0	7
60	Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography. Anticancer Research, 2017, 37, 877-882.	1.1	7
61	Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma. Anticancer Research, 2017, 37, 1729-1735.	1.1	7
62	Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation. Anticancer Research, 2017, 37, 2619-2623.	1.1	6
63	Pulmonary vein stump thrombosis after left pneumonectomy, diagnosed based on a high plasma D-dimer level: a case report. Journal of Thoracic Disease, 2017, 9, E210-E214.	1.4	5
64	LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma. Anticancer Research, 2020, 40, 5659-5666.	1.1	5
65	Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer. Anticancer Research, 2017, 37, 3307-3309.	1.1	5
66	Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors. Anticancer Research, 2018, 38, 1715-1719.	1.1	5
67	Application of Continuous Negative Pressure Irrigation and Negative Pressure Fixation to Treat a Bronchopleural Fistula with Thoracic Empyema. Journal of the American College of Surgeons, 2014, 218, e87-e90.	0.5	4
68	Detectability of T1a lung cancer on digital chest radiographs: an observer-performance comparison among 2-megapixel general-purpose, 2-megapixel medical-purpose, and 3-megapixel medical-purpose liquid-crystal display (LCD) monitors. Acta Radiologica, 2015, 56, 943-949.	1.1	4
69	Esophageal cancer associated with bilateral hilar lymphadenopathy caused by sarcoid-like reactions: a report of two cases. Esophagus, 2015, 12, 322-326.	1.9	4
70	The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis. Cancer Medicine, 2018, 7, 2860-2867.	2.8	4
71	Mutational signatures in squamous cell carcinoma of the lung. Journal of Thoracic Disease, 2021, 13, 1075-1082.	1.4	4
72	Rib metastasis appearing 8 years after surgery for lung cancer: Report of a case. Surgery Today, 2000, 30, 462-464.	1.5	3

#	Article	IF	CITATIONS
73	The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. Annals of Surgical Oncology, 2019, 26, 1544-1551.	1.5	3
74	Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients., 2017, 37, 5871-5876.		3
75	Cardiac tamponade due to bleeding as a potential lethal complication after surgery for esophageal cancer. Anticancer Research, 2015, 35, 407-11.	1.1	3
76	Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer. Anticancer Research, 2015, 35, 1791-6.	1.1	3
77	A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis. Anticancer Research, 2017, 37, 6937-6941.	1.1	2
78	Reply to "EGFR Mutation in Patients with Lung Adenosquamous Cell Carcinoma― Annals of Surgical Oncology, 2017, 24, 676-676.	1.5	1
79	Highlighted version successful resection of a tracheal metastasis of rectal cancer: a case report. Journal of Thoracic Disease, 2017, 9, E797-E800.	1.4	1
80	HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome. Transplant Immunology, 2019, 53, 13-20.	1.2	1
81	Applicability of Pulmonary Lobectomy in Treating Metastatic Lung Tumors. Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 189-193.	0.8	1
82	Liver transplantation followed by pulmonary resection complicated with end-stage liver cirrhosis: a case report. Anticancer Research, 2015, 35, 3411-4.	1.1	1
83	Prognostic impact of cell type under the seventh TNM staging system in resected nonâ€small cell lung cancer. Thoracic Cancer, 2012, 3, 249-254.	1.9	О
84	A case of anterior mediastinal malignant lymphoma complicated by lung adenocarcinoma. The Journal of the Japanese Association for Chest Surgery, 2015, 29, 78-83.	0.0	0
85	A case of surgical treatment for systemic origin of an aberrant artery to the basal segments of the left lung. The Journal of the Japanese Association for Chest Surgery, 2016, 30, 236-242.	0.0	0
86	Underlying Problems in Surgical Treatment of cT1-2N1 Non-Small Cell Lung Cancer. Thoracic and Cardiovascular Surgeon, 2017, 65, 130-135.	1.0	0
87	Molecular mechanism of in vitro pemetrexed sensitivity according to histological type in non-small cell lung cancer Journal of Clinical Oncology, 2012, 30, e13090-e13090.	1.6	0
88	Implantation of Hepatocellular Carcinoma along the Needle Tract to the Skin, Chest Wall, and Diaphragm Two Years and Nine Months after Biopsy— Case Report— Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2014, 75, 2274-2279.	0.0	0